Table 1.

General characteristics of included studies (about the relationships between CD133 expression and OS or PFS in glioma patients)

First author	Year	Origin country	No. of patients	Median/mean age (year)	WHO grade	Detect method	Cut off level	Survival end points	Follow up period	Survival analysis	Adjusted variables
Ardebili [10]	2011	Slovenia	24	mean 60	IV	QRT-PCR	30 000 (─, 2-ΔΔCt > 30.000)	OS	NR	univariate (KM)	NR
Kase [11]	2013	Estonia	42	30–77	IV	IHC	median	OS	NR	multivariate	Radiotherapy dose, Chemotherapy, Karnofsky performance score
Kim [12]	2011	Korea	88	mean 54.9 (13–80)	IV	IHC	50 %	OS	mean 13.9 months (1–53)	multivariate	age, sex, Karnofsky performance scale (KPS) score, extent of removal, chemoradiotherapeutic modality, temozolomide modality, after temozolomide therapy and stem cell marker expression
								PFS
Melguizo [13]	2012	Italy	75	24–81	IV	IHC	25 %	OS	NR	multivariate (KM)	NR
								PFS
Metellus [14]	2011	France	48	mean 60.1 ± 9.2	IV	QPCR	1.03	OS	Median 18.9 months	multivariable	Age, extent of surgery, MGMT status (MethyLight)
								PFS
Shibahara [15]	2013	Japan	112	Media 57 (7–77)	IV	WB	CD133/b-actin ratio = 1	OS	Median 25.7 months (3–152)	multivariable	Ki67 LI (≥35 %), 9p homozygous deletion and 10q loss
Shin [16]	2013	Korea	67	NR	IV	IHC	50 %	OS	NR	multivariable	status
								PFS
Zeppernik [17]	2008	Germany	48	NR	II–III	IHC	1 %	OS	mean 86 months (±39)	multivariate	age, WHO grade and extent of resection
								PFS
Dahlrot [18]	2014	Denmark	25	NR	II	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status
								PFS
Dahlrot [18]	2014	Denmark	26	NR	III	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status
								PFS
Dahlrot [18]	2014	Denmark	185	NR	IV	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status
								PFS